Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Medical cannabis company Kanabo reported a loss for the half year ended 30 June 2021, largely due to the one-off costs associated with the reverse acquisition.
The company completed the reverse take-over of Kanabo Research on 16 February 2021.
The company's pre-revenue status is reflected in the operating loss of £1.2 million for the six-month period.
The total loss for this period was £2.4 million.
The balance sheet had cash reserves of £5.9 million as of 30 June 2021.